Clinical Trial Update: Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of Zevalin (ibritumomab tiuxetan) and Velcade (bortezomib) for relapsed/refractory mantle cell lymphoma was terminated; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Velcade (bortezomib)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Duke University | Conditions: Mantle-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2015-06-04